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Abstract
Introduction To investigate the combined performance of quantitative CT (qCT) following a computer algorithm analysis
(IMBIO) and 18F-FDG PET/CT to assess survival in patients with idiopathic pulmonary fibrosis (IPF).
Methods A total of 113 IPF patients (age 70 ± 9 years) prospectively and consecutively underwent 18F-FDG PET/CT and high-
resolution CT (HRCT) at our institution. During a mean follow-up of 29.6 ± 26 months, 44 (48%) patients died. As part of the
qCT analysis, pattern evaluation of HRCT (using IMBIO software) included the total extent (percentage) of the following
features: normal-appearing lung, hyperlucent lung, parenchymal damage (comprising ground-glass opacification, reticular pat-
tern and honeycombing), and the pulmonary vessels. The maximum (SUVmax) and minimum (SUVmin) standardized uptake
value (SUV) for 18F-FDG uptake in the lungs, and the target-to-background (SUVmax/SUVmin) ratio (TBR) were quantified using
routine region-of-interest (ROI) analysis. Pulmonary functional tests (PFTs) were acquired within 14 days of the PET/CT/HRCT
scan. Kaplan–Meier (KM) survival analysis was used to identify associations with mortality.
Results Data from 91 patients were available for comparative analysis. The average ± SD GAP [gender, age, physiology] score
was 4.2 ± 1.7 (range 0–8). The average ± SD SUVmax, SUVmin, and TBR were 3.4 ± 1.4, 0.7 ± 0.2, and 5.6 ± 2.8, respectively. In
all patients, qCT analysis demonstrated a predominantly reticular lung pattern (14.9 ± 12.4%). KM analysis showed that TBR
(p = 0.018) and parenchymal damage assessed by qCT (p = 0.0002) were the best predictors of survival. Adding TBR and qCT to
the GAP score significantly increased the ability to differentiate between high and low risk (p < 0.0001).
Conclusion 18F-FDG PET and qCT are independent and synergistic in predicting mortality in patients with IPF.
Keywords Idiopathicpulmonary fibrosis .Quantitativecomputer analysis . Positronemission tomography .Fluorine-18FDGand
pulmonary vessels
Introduction
High-resolution CT (HRCT) is the current imaging reference
standard in the investigation of patients with idiopathic pul-
monary fibrosis (IPF), revealing structural details of the entire
lung parenchyma which reflect the characteristic histological
changes. However, HRCT is conventionally a purely structur-
al, qualitative imaging technique and requires dedicated radio-
logical training to assess the severity of disease [1, 2]. Several
computer-based quantitative CT (qCT) methods have been
developed to precisely quantify the extent of disease [3].
However, despite showing a significant correlation with both
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visual score and pulmonary function tests (PFTs), qCT has yet
to provide insight into the mechanisms and activity of fibrosis
and disease progression. The ability to radiologically quantify
the response of individual patients to treatment would be an
important advance given the current lack of end points for
drug trials in IPF [4].
Positron emission tomography (PET) offers the means for
non-invasive investigation of cellular metabolism in vivo.
PET studies in animals have yielded potentially valuable in-
sight into the biology of IPF, with heightened 18F-
fluorodeoxyglucose (18F-FDG) PET signal intensity related
to interstitial lung changes [5, 6]. 18F-FDG pulmonary uptake
on PET has been shown to relate to disease severity as
assessed by quality-of-life measurement, lung volume, and
gas transfer, and more recently it was shown that baseline
objective measures of 18F-FDG uptake on PET predict patient
survival, independent of PFTs [7, 8].
Given the need for biomarkers in patients with IPF for risk
stratification and drug development, we investigated the po-
tential synergistic application of pulmonary18F-FDG PETsig-
nal with qCT to predict survival in IPF. We compared this
synergistic approach with the clinical gender-age-physiology
(GAP) scoring system for prognostic accuracy [9].
Materials and methods
From January 2008 to December 2017, a total of 113 (93
male, 20 female, mean age 70 ± 8.9 years) prospective and
consecutive patients with IPF underwent 18F-FDG PET/CT/
HRCT at our institution. The entire cohort was previously
reported in a study assessing only FDG PET [8]. In the present
study, a subgroup of that cohort is used for additional analysis
(qCT) to compare and explore the synergistic value of qCT as
compared to the previously reported FDG PET findings. All
patients underwent full clinical assessment and baseline pul-
monary function tests (PFTs).
All patients were referred from primary and secondary care
to the UCLH NHS-England Specialist Centre for the diagno-
sis and management of interstitial lung diseases (ILDs). The
mean average time from first visit to our tertiary care center
was 15 ± 10 months (4–23 months), and patients displayed a
wide variation in levels of dyspnea when first assessed.
Patients with symptoms of acute infection and lung malig-
nancy were excluded. Diagnosis of IPF was made on clinical
and radiological grounds following multidisciplinary team
(MDT) review. The MDT comprises specialists including at
least two ILD-trained radiologists, three specialist ILD respi-
ratory physicians, a specialist nurse and a lung pathologist. A
dedicated clinical assessment and investigations were used to
rule out other possible causes of usual interstitial pneumonitis
(UIP) that can give the same radiological picture as IPF. This
includes other fibrosing ILDs such as hypersensitivity pneu-
monitis, sarcoidosis, and rheumatoid arthritis.
The study was approved by the ethics board (London-
Harrow Research Ethics Committee [REC reference 06/
Q0505/22]), and all patients provided written informed
consent.
The follow-up period was defined from the date of scan to
death (all causes) or 9 years, whichever happened first. Repeat
scans were performed when clinically indicated, and not rou-
tinely unless this affected patient management, according to
National Institute for Health and Care Excellence (NICE) IPF
clinical guidelines.Patient survival was confirmed by the use
of patient charts, electronic database, primary health care phy-
sician records, or telephone interview.
The GAP index was computed based on four variables:
gender (G), age (A), and two lung physiology (P) parameters,
forced vital capacity (FVC) and transfer factor of the lung for
carbonmonoxide (TLCO) [10]. This comprised a model using
continuous predictors (GAP calculator) and a simple point-
scoring system (GAP index), which varies from 0, potentially
indicating a good outcome, to 8, potentially indicating a worse
outcome.
Based on the GAP index, the three stages identified are as
follows: GAP stage I included GAP index 0, 1, 2, 3; GAP
stage II included GAP index 4, 5; and GAP stage III included
GAP index 6, 7, 8.
PET/CT acquisition
The PET/CT scans were obtained using a 64-slice multidetec-
tor CT scanner (VCT PET/64, GE Healthcare, Chicago, IL,
USA).
Three imaging sequences of the thorax were performed
while the patient remained supine on the table throughout. A
CT scan was performed for attenuation correction. With the
patient maintaining the supine position, a chest 18F-FDG PET
emission scan (8 min/bed position) was performed 1 h after
injection of 200 MBq of 18F-FDG.
After completion of the PET/CT, with the patient maintain-
ing the same supine position, an HRCT (volumetric 1-mm full
inspiration scan, peak voltage of 120 kVp, tube current mod-
ulation range 30–140 mA, B70 kernel reconstruction) was
performed.
Image display and processing
PET/CT images were analyzed by a dedicated thoracic radi-
ologist and senior PET technologist with more than 10 years
of experience in quantifying pulmonary 18F-FDG PET uptake
in ILD and examining HRCT.
All images were loaded onto a dedicated workstation.
Using a volumetric region of interest, the area of most intense
pulmonary 18F-FDG uptake was identified and the highest
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value (SUVmax) measured. In addition, the region of pulmo-
nary parenchyma considered mostly normal on CT by the
expert thoracic radiologist, with the lowest SUV, was identi-
fied and the SUVmin in this region recorded. The target-to-
background ratio (TBR = SUVmax/SUVmin) was also recorded
as a standard measurement [11].
QCTanalysis on HRCTwas undertaken using IMBIO soft-
ware (the technical features have been described [12] previ-
ously). Briefly, evaluation of HRCT data involved algorithmic
identification and volumetric quantification of every voxel
volume unit into one of the following radiologic parenchymal
features: normal-appearing lung, hyperlucent lung, ground-
glass opacification, reticular pattern, honeycombing, and the
pulmonary vessels. Volumes were then converted into per-
centages using, as reference, the total volume of the lungs as
measured by the software. A synthetic value was created by
adding up ground-glass opacification, reticular pattern, and
honeycombing to express the total burden of disease in the
lung parenchyma.
Statistical analysis
Statistical analyses were performed using RStudio version
1.1.463 (RStudio Inc., Boston, MA, USA) for Macintosh
based on R version 3.5.1 (R Foundation for Statistical
Computing).
Correlations between the area of highest pulmonary 18F-
FDG uptake (SUVmax), lowest pulmonary
18F-FDG uptake
(SUVmin), TBR, extent of qCT parenchymal patterns, and
individual PFTs were explored with Spearman’s correlation
coefficient and displayed using a correlation matrix; to ac-
count for multiple comparisons, the Bonferroni correction
was applied (p < 0.0042).
The survival analysis was performed using the package
‘survminer’ (https://cran.r-project.org/web/packages/
survminer/) and its dependencies. To explore the
relationships of imaging-derived parameters (PET and qCT),
PFTs, and GAP with patient survival, a Kaplan–Meier (KM)
survival analysis was calculated for each of the parameters.
Patients that were alive at the time of the follow-up collection
were censored. Initially, the median value was chosen as a
threshold (cutoff) to divide the cohort into two groups accord-
ing to their prognosis (poor and good prognostic groups).
Subsequently, optimal cutoffs that best separated the survival
plots were determined (lowest p value). KM curves displaying
patients above and below each threshold were generated to
facilitate the visualization of the survival trend of the two
populations. Subsequently, the parameters that were found to
significantly discriminate between the prognostic groups were
used as input for a multivariate stepwise (forward and back-
ward) Cox regression. The variables to be retained at each step
were determined using the Akaike information criterion.
In all the analyses that were not corrected for multiple com-
parison, p values <0.05 were considered significant.
Modified PET and qCT score
The potential synergistic effect of GAP and imaging-derived
biomarkers (PET and qCT) in prognostication was assessed
creating a novel score based on the GAP index.We propose to
add to the GAP index another factor based on the best predic-
tor for PET (either SUVmax, SUVmin or TBR) according to the
prognostic ability of the biomarker to create a synthetic score
based on the imaging test as previously described [8] (hereaf-
ter called GAP_PET). Similarly, we propose to use the best
biomarker derived from the qCT analysis as an added factor
for a third modified score (hereafter GAP_PET_qCT).
According to the best cutoff point previously determined, im-
aging biomarkers were binarized in adverse (coded as 1) or
favorable (coded as 0) biomarkers. This was subsequently
added to the existing GAP index value, resulting in
GAP_PET ranging from 0 to 9 and GAP_PET_qCT ranging
from 0 to 10, as compared to the standardGAP index, which is
from 0 to 8. The new scores redefined the stages as follows:
stage I for GAP_PET as 0–3 and for GAP_PET_qCT as 0–4;
stage II for GAP_PETas 4–6 and for GAP_PET_qCTas 5–7;
and stage III for GAP_PET as 7–9 and for GAP_PET_qCT as
8–10.
Results
The HRCT was not analyzable by the qCT software in 22
patients. Reasons for failure were motion artifacts in 17 pa-
tients and incorrect reconstruction kernel in 5 patients. Thus,
91 patients with IPF were included and analyzed for this com-
parative FDG PET/qCT study.
Of the retained patients, 78 (85.7%) were male, and 23
(25.3%) were treated with pirfenidone. At baseline, the aver-
age GAP index was 4.2 ± 1.7 (0–8); 31 patients (34.4%) were
classified as GAP stage I, 38 patients (42.2%) were GAP stage
II, and the remaining 21 patients (23.3%) were classified as
stage III; one patient was excluded from the GAP analysis
because the FVC was unobtainable. Values of FVC, forced
expiratory volume in 1 s (FEV1), total lung capacity (TLC),
carbon monoxide transfer coefficient (KCO), and TLCO are
shown in Table 1. The mean follow-up period was 29.6 ±
26 months (0–109.4); during this time, 47 (51.6%) patients
died. Cause of death was as follows: exacerbation of IPF (17
[37%]), pulmonary embolism (3 [6%]), pneumonia (14
[31%]), heart failure/cor polmonale (6 [12%]), 3 cancer (2
lung and 1 colon [6%]), and 4 unknown (8%).
The mean SUVmax was 3.4 ± 1.4 (1.5–10.7), the mean
SUVmin (background lung activity) was 0.7 ± 0.2 (0.3–1.3),
and the mean TBR 5.7 ± 2.8 (2.2–21.4). The results of the
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qCT analysis are shown in Table 2; the predominant pattern
was reticular lung, with an average percentage of 14.9 ±
12.4% (0.3–74.5); on average, 71.8 ± 16% (19.2–94) of lung
parenchyma was deemed normal.
Bivariate analysis
Correlations between the area with highest pulmonary 18F-
FDG uptake (SUVmax), lowest pulmonary uptake (SUVmin),
TBR, extent of qCT parenchymal patterns, and individual
PFTs are shown in Fig. 1. The imaging-derived parameters
available from the qCT software correlated significantly
among themselves (0.0000 < p < 0.004), acting as internal val-
idation for the software itself. Of the PFTs, only TLC was
correlated with an imaging biomarker (SUVmin); this correla-
tion was negative (r = −0.76; p = 0.0025).
Univariate and multivariate survival analysis
The KM analysis was performed for all the clinical variables
(PFTs and GAP) and the imaging-derived biomarkers (PET
and qCT); results are summarized in Table 3.
The KM analysis using the median as cutoff value
demonstrated that all the PFTs with the exception of the
TLC (p = 0.21) were able to significantly differentiate pa-
tients according to survival, with the strongest predictor
being the TLCO (p = 0.0004). Of the PET-derived bio-
markers, TBR was a significant predictor of patient sur-
vival (p = 0.019); curves are shown in Fig. 2. The synthet-
ic score generated to express the total burden of paren-
chymal damage evaluated by qCT was significantly pre-
dictive of patient outcome (p = 0.0013); however, the
strongest predictor of patient outcome from the qCT pa-
rameters was the vessel percentage (p = 0.0001; Fig. 3).
The KM analyses were then repeated using the optimal
cutoff as threshold for the groups’ separation. Optimal
cutoff and corresponding median survival are shown in
Table 4. SUVmax and SUVmin were confirmed to be
non-predictive of patient outcome (p = 0.081 and p =
Table 1 Pulmonary function tests (PFTs) obtained at baseline
PFTs Value
FVC 74.9 ± 17.6 (37–122)
FEV1 77.1 ± 16.5 (31.8–129)
TLC 69.9 ± 11.1 (48–91)
KCO 77.8 ± 21.7 (27–135)
TLCO 45.3 ± 14.4 (11–79)
GAP index 4.2 ± 1.7 (0–8)
Figures are expressed as mean ± standard deviation (range). FVC =
forced vital capacity, FEV1 = forced expiratory volume in 1 s, TLC =
total lung capacity, KCO = carbon monoxide transfer coefficient,
TLCO= transfer factor of the lung for carbon monoxide. The GAP index
was obtained as per Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti
S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr,
Collard HR. A multidimensional index and staging system for idiopathic
pulmonary fibrosis. Ann Intern Med. 2012 May 15;156(10):684-91. doi:
https://doi.org/10.7326/0003-4819-156-10-201,205,150-00004. PubMed
PMID: 22586007)




SUVmax 3.4 ± 1.4 (1.5–10.7)
SUVmin 0.7 ± 0.2 (0.3–1.3)
TBR 5.7 ± 2.8 (2.2–21.4)
qCT
Normal parenchyma (%) 71.8 ± 16 (19.2–94)
Normal parenchyma (cm3) 2986.1 ± 1236.6 (83.9–5600)
Hyperlucent (%) 5 ± 6.9 (0.00005–26)
Ground-glass (%) 6.3 ± 8.6 (0.04–50.6)
Reticular (%) 14.9 ± 12.4 (0.3 ± 74.5)
Honeycomb (%) 1.8 ± 2.2 (90–9.3)
Parenchymal damage (%) 23 ± 16.7 (0.8–80.8)
Vessels (%) 3.9 ± 1.6 (0.9–9.8)
Vessels (cm3) 147.5 ± 47.9 (67.1–304.7)
Values are expressed as mean ± standard deviation (range)
Fig. 1 Correlation matrices among the highest pulmonary 18F-FDG
uptake (SUVmax), lowest uptake (SUVmin), TBR, extent of qCT
parenchymal patterns, and GAP index and stage. Correlations were
explored using Spearman’s correlation coefficient; to account for
multiple comparisons, the Bonferroni correction was applied. A value
of 1 indicates complete positive correlation; a value of −1 indicates
complete negative correlation. *Indicates statistical significance
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0.12 respectively). Patients with TBR < 4.8 had a median
survival of 70.6 months as compared to 26.5 months in
patients with TBR > 4.8 at the baseline PET (p = 0.018).
The synthetic score of parenchymal damage demonstrated
a slightly better performance than TBR; patients with
values <18.5 had a median survival of 70.6 months as
compared to 22.2 months in patients that presented a
higher burden of parenchymal damage (p = 0.0002).
The parameters that significantly predicted outcome with
KM analysis were used as the input for the Cox multivariate
analysis and the Cox forward stepwise regression analysis;
results are shown in Table 5. The stepwise regression con-
firmed that TBR is an independent prognostic predictor (p =
0.01). Moreover, in a model constructed including the qCT
parameters, the forward stepwise Cox regression analysis con-
firmed that the volume of normal parenchyma, the vessels,
and the hyperlucent pattern are independent prognostic indi-
cators (p = 0.03, p = 0.01 and p = 0.01, respectively).
Modified GAP score
The results of the KM analysis conducted on the incre-
mental scores (GAP_PET and GAP_PET_qCT) obtained
by modifying the GAP score are presented in Fig. 4. The
two incremental scores were all significantly able to pre-
dict patient survival (p < 0.0001); however, their ability to
predict median survival differed (Table 6). Using an opti-
mal cutoff of 6, the GAP_PET showed a median survival
of 43.9 months in patients with a score lower than the
cutoff, and median survival of 11.6 months in patients
above the cutoff. The GAP_PET_qCT score showed an
Table 3 Results of Kaplan–Meier analysis conducted using the median
values as cutoff to discriminate between the two groups (presence or lack
of event during follow-up)













Total volume (cm3) 4103.86 0.2
Vessel percentage (%) 3.80 <0.0001
Normal parenchyma (%) 74.56 0.011
Hyperlucent (%) 2.05 0.69
Ground-glass (%) 2.80 0.017
Reticular (%) 11.46 <0.0001
Honeycomb (%) 0.71 0.5
Parenchymal damage (%) 18.94 0.0013
FVC= forced vital capacity, FEV1 = forced expiratory volume in 1 s,
TLC = total lung capacity, KCO= carbon monoxide transfer coefficient,
TLCO= transfer factor of the lung for carbon monoxide
Fig. 2 Kaplan–Meier plots of survival analysis. Patients were classified
according to their median (a is SUVmax, b is SUVmin, and c is TBR) and
according to the optimal cutoff (d is SUVmax, e is SUVmin, and f is TBR)
values as described in the methods section. The log-rank test
demonstrated a statistically significant worse prognosis in patients with
TBR greater than 5 (median value, p = 0.019, curve c) and 4.8 (optimal
cutoff, p = 0.018, curve f). Using the optimal cutoff for all the parameters
improved the capacity of differentiating between patients with better and
worse prognosis; however, SUVmax (a and d) and SUVmin (b and e) were
not statistically significant
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improvement in outcome prediction, particularly in the
worst outcome group, with a median survival of
86.5 months in patients with a score lower than 6, and
median survival of 17.2 months in patients with a score
above the cutoff.
Discussion
Our study has shown that in IPF patients, the baseline mea-
sures of FDG PET and several qCT parameters in HRCT are
potential independent biomarkers related to patient survival.
Their combined use can have a synergistic effect in the assess-
ment of disease prognosis. These data demonstrate that in IPF
patients, both pulmonary glucose uptake and qCT are inde-
pendent prognostic factors. Moreover, these factors are syner-
gistic and may offer better outcome modeling than current
GAP analysis alone. This is potentially important in IPF
patients, where there is a lack of validated biomarkers for risk
stratification and therapeutic intervention.
Among the PET parameters, patients with a high TBR had
a worse prognosis, while for the qCT, the percentage of nor-
mal parenchyma and the percentage of vessels (higher % cor-
responding to worse prognosis) were the strongest indepen-
dent imaging biomarkers of survival (Table 4). These findings
confirm data previously reported elsewhere [13].
The unexpected signal provided by pulmonary vessel
volume (PVV) in this study has been described but is not
fully comprehensible. Jacob et al. provided three plausible
explanations: 1) blood-flow diversion from advanced fi-
brotic areas to relatively spared lung regions, with aber-
rant dilatation of capacitance vessels resulting in in-
creased PVV; 2) dilatation effect on blood vessels of in-
creased negative pressure during inspiration due to in-
creased lung stiffness in IPF patients; and 3) the effect
of pleuroparenchymal and bronchopulmonary arterial
anastomosis [14].
Fig. 3 Kaplan–Meier plots of survival analysis. Patients were classified
according to their median (a is parenchymal damage, b is total vessel
percentage) and according to the optimal cutoff (d is parenchymal
damage and e is total vessel percentage) values, as described in the
methods section. The parenchymal damage was obtained by adding up
ground-glass opacification, reticular pattern, and honeycombing to
express the total burden of disease in the lung parenchyma; the total
vessel percentage reflects the percentage of vessels in the lung
parenchyma. The log-rank test demonstrated a statistically significant
worse prognosis in patients with parenchymal damage greater than 18.9
(median value, p = 0.0013, curve a) and 18.5 (optimal cutoff, p = 0.0002,
curve c). Similarly, a vessel percentage greater than 3.8% (median value,
p < 0.0001, curve b) and 3.66% (optimal cutoff, p < 0.0001, curve d)
predicted significantly worse prognosis. Using the optimal cutoff
calculated in R improved the capacity to differentiate between patients
with better and worse prognosis, using both parenchymal damage and
total vessel percentage
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Further explanations have been also proposed, including
the presence of vascular abnormalities in fibrotic lungs, dem-
onstrated histologically and reminiscent of pulmonary venous
occlusive disease with aberrant capillary duplication. The re-
ported increased vascular volume was found in less affected
areas of the lung and correlated with pulmonary arterial pres-
sure as estimated by transthoracic echocardiography [15].
It is interesting that PET is able to detect subtle metabolic
changes in visually normal or minimally involved lung in
patients with IPF [16]. In this regard, the combined applica-
tion of metabolic, morphological, and quantitative informa-
tion may enable more accurate assessment of early disease,
for example, to determine whether the subtle changes seen on
FDG PETare in fact due to regional increases in blood flow in
areas of limited interstitial lung pathology.
When we combined the pulmonary PET uptake, qCT, and
PFT parameters, we found that the combination of these three
independent parameters had the strongest association with
survival. In fact, even in IPF patients with good PFTs, the
pulmonary 18F-FDG uptake and the extent of morphological
abnormalities on HRCTmight help identify subpopulations of
patients that had a poorer outcome [8]. Using qCT and PET,
we created two modified versions of the GAP score that im-
proved the capacity to classify patients according to their out-
come at the follow-up using baseline tests. This may have
relevance in the clinical setting in determining treatment rec-
ommendations based on a combination of the three indepen-
dent variables (GAP + qCT + PET).
The synergies between GAP, PET, and qCT are encour-
aging. In GAP stage I, we identified IPF patients with a
worse outcome than the other GAP I patients, and they
may have benefited from treatment. Likewise, there were
patients in GAP stage II and particularly III that showed
lower 18F-FDG uptake and qCT parameters, whose out-
come was more favorable. This may have important clin-
ical implications, as with our data we were able to re-
classify many patients from GAP III into the new modi-
fied GAP I score despite impaired lung function (FVC <
80% predicted), compared to a group of patients with
mildly impaired lung function (FVC > 80% predicted) that
progressed rapidly. Thus, the synergistic use of 18F-FDG
PET and qCT in this context raises the possibility for
more accurate selection of patients that may benefit most
from pirfenidone or nintedanib treatment from a wider
patient population.
Table 4 Median survival obtained from Kaplan–Meier analysis
conducted using the optimal cutoff to discriminate between the two
groups (presence or lack of event during follow-up)
Parameter Cutoff Median survival p value
< Cutoff > Cutoff
Pulmonary function tests
FVC 72 26.37 86.47 0.0044
FEV1 96.3 35.37 70.6 0.02
TLC 65.6 28.57 86.73 0.027
KCO 50 19.9 46.8 0.00097
TLCO 44.8 23.53 70.60 0.00027
GAP index 4 70.6 19.9 0.00046
PET-derived parameters
SUVmax 2.4 86.73 34.43 0.081
SUVmin 0.6 26.53 67.50 0.12
TBR 4.8 70.60 26.53 0.018
qCT
Total volume (cm3) 4352.77 28.57 80.93 0.011
Vessel percentage (%) 3.66 86.47 19.90 <0.0001
Normal parenchyma (%) 80.20 26.37 86.37 0.00029
Hyperlucent (%) 11.12 46.80 22.23 0.0038
Ground-glass (%) 6.79 67.5 16.3 <0.0001
Reticular (%) 10.96 70.60 26.53 0.004
Honeycomb (%) 4.23 40.80 16.63 0.0022
Parenchymal damage (%) 18.48 70.60 22.23 0.0002
Synthetic scores
GAP + PET 6 43.90 11.56 <0.0001
GAP + PET + qCT 6 86.47 17.23 <0.0001
FVC= forced vital capacity, FEV1 = forced expiratory volume in 1 s,
TLC = total lung capacity, KCO= carbon monoxide transfer coefficient,
TLCO= transfer factor of the lung for carbon monoxide
Table 5 Cox modelling of survivals according to pulmonary function
tests, TBR, and qCT parameters
Parameter Hazard ratio (95% CI) p value
Pulmonary function tests
FVC 0.99 (0.90–1.11) 0.997
FEV1 0.99 (0.91–1.07) 0.775
TLC 0.94 (0.86–1.02) 0.155
KCO 0.96 (0.90–1.02) 0.146
TLCO 0.99 (0.87–1.12) 0.849
GAP index 3.77 (1.12–12.69) 0.032
PET-derived parameters
TBR 1.09 (1.00–1.19) 0.043
qCT
Total volume (cm3)
Vessel percentage (%) 2.57 (1.04–6.38) 0.0414
Normal parenchyma (%) 5.22 (4.75–5.73) 0.9202
Hyperlucent (%) 5.12 (4.63–5.67) 0.9211
Ground-glass (%) 4.76 (4.32–5.25) 0.9246
Reticular (%) 4.74 (4.32–5.20) 0.9249
Honeycomb (%) 5.00 (4.57–5.46) 0.9223
Parenchymal damage (%) 1.09 (0.99–1.19) 0.008
FVC = forced vital capacity, FEV1 = forced expiratory volume in 1 s
TLC = total lung capacity, KCO= carbon monoxide transfer coefficient,
TLCO= transfer factor of the lung for carbon monoxide
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HRCT is the main diagnostic imaging tool in IPF, but until
recently there have been only limited data on the prognostic
use of this imaging technique. This may be because in many
cases, the morphological appearance does not allow for accu-
rate and reproducible assessment [17]. However, a number of
studies investigating the association between mortality and
different variables, including normal lung, centrilobular em-
physema, and number of vessels, have shown qCT to be su-
perior to visual HRCTscoring [18]. qCT-derived features have
also outperformed visual CT patterns in predicting outcome
across several fibrosing lung diseases other than IPF.
One of the best known software algorithms, CALIPER
(Computer-Aided Lung Informatics for Pathology Evaluation
and Rating), based on lung texture analysis, was developed at
the Biomedical ImagingResource,MayoClinic, Rochester,MN,
USA. This software has been shown to be reproducible and
robust across a wide variety of acquisition and reconstruction
techniques, including low- and ultralow-dose (0.1–0.3 mSv)
CT techniques with both filtered back-projection and iterative
reconstruction. The model proposed in our study is based on
CALIPER and provides a detailed map of lung textures that
are key to identifying ILDs and other fibrotic conditions [18].
Jacob et al. recently reported their application of CALIPERquan-
titative HRCT in IPF patients, showing that stratification using
CALIPER variables and PFTs provided a stronger mortality sig-
nal than stratification using the GAP index alone [13].
The technical protocol we have developed in this study is
novel and uses a low-dose HRCT acquired in breath-hold at the
end of half-dose FDG PET. This combined quantitative approach
may pave the way for more detailed longitudinal studies.
However,we recognize that there are limitations: several technical
factors related to qCT and PET need to be improved. Regarding
qCT, several analytical methods have been described (e.g. seg-
mentation and feature extraction based on lung density [measured
in Hounsfield units]), all heavily influenced by CT dose, slice
thickness, and reconstruction kernels. In our study, slightly differ-
ent HRCTacquisition protocols adopted at the start of our recruit-
ment since 2006 led to the exclusion of some patients due to
different reconstruction methods or scanning protocols.
Limitations of PET imaging also need to be recognized,
such as the importance of air and tissue fraction and motion
correction. For example, in the normal lung, previous studies
showed that the uptake distribution without air fraction cor-
rection (AFC) appeared uniform throughout the lung, but on
correcting for the air component, the results for the regional
uptake changed [19, 20]. Also, future studies need to explore
the use of texture heterogeneity analysis as part of the overall/
comprehensive qCTanalysis techniques, which could provide
additional insight into morphological feature extraction [21].
We also acknowledge that the imaging was not always
performed at the time of diagnosis, which is a common prob-
lem for imaging studies, as patients often present at later
stages of the disease.
We recognize that our combined approach is not feasible
for all patients, as it is time-consuming and is not always
financially justifiable. On the other hand, current therapies
for IPF are expensive and often limited by side effects, and
not all patients may benefit from them. There are no validated
Fig. 4 Kaplan–Meier plots of survival analysis. Patients were classified
according to the optimal cutoff values as described in the methods
section; a represents the GAP index, b is GAP_PET (obtained from the
addition of GAP and TBR), and c is GAP_PET_qCT (obtained adding
the qCT to the GAP_PET); additional details on the synthetic score can be
found in the methods section. The log-rank test demonstrated that all the
scores were statistically significant predictors of survival (p values in
corresponding panel); however, adding information from PET and qCT
improved the ability to differentiate between a better and worse prognosis
Table 6 Distribution of patients (expressed as n) according to the risk category as defined by GAP index, GAP PET values, and quantitative CT
parameters and their corresponding average survival (expressed in months)
Scoring system Low risk Intermediate risk High risk
Patients (n) Survival (months) Patients (n) Survival (months) Patients (n) Survival (months)
GAP index 31 33.3 38 29.3 21 24.4
GAP index + PET 41 35.0 36 27.6 14 19.5
GAP index + PET + qCT 54 36.3 25 21.8 12 16.3
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disease response biomarkers available, and our combined ap-
proach may refine the stratification of this heterogenous group
of patients, as well as speed the assessment of novel therapies,
and enable a personalized approach in selected cases.
Finally, although the PETand HRCTacquisition scans can be
done on different scanners and the results of the two techniques
evaluated independently, some newer PET/CT scanners allow
simultaneous HRCT/PET acquisition in breath-hold, reducing
the time for a double scan and limiting ionizing radiation.
Conclusion
We have shown that high pulmonary uptake of 18F-FDG and
several qCT parameters are associated with mortality in pa-
tients with IPF. These PET and qCT findings can be used
synergistically with PFTs and could help offer a personalized
approach to treatment for individual patients.
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